Erastin: A Benchmark Ferroptosis Inducer for Oncology and Redox Biology

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that selectively induces ferroptosis, an iron-dependent, non-apoptotic form of cell death, in tumor cells with RAS or BRAF mutations (Zhang et al., 2023). Its mechanism centers on inhibition of the cystine/glutamate antiporter system Xc⁻ and modulation of VDAC, disrupting redox homeostasis and elevating lipid peroxides. Erastin is insoluble in water/ethanol and is optimally dissolved in DMSO at ≥10.92 mg/mL. APExBIO provides Erastin (SKU B1524) as a high-purity research reagent, widely referenced in cancer biology and oxidative stress pathway studies. Typical experimental conditions involve 10 μM Erastin treatment of engineered or HT-1080 tumor cells for 24 hours.

Biological Rationale

Ferroptosis is a regulated cell death pathway characterized by iron-dependent accumulation of lethal lipid peroxides (Zhang et al., 2023). Tumor cells with mutations in RAS family genes (HRAS, KRAS) or BRAF exhibit increased sensitivity to oxidative damage and ferroptosis due to metabolic reprogramming and elevated reactive oxygen species (ROS) (Fusion Glycoprotein, 2023). The system Xc⁻/GSH/GPX4 axis is a crucial antioxidant defense; its disruption leads to redox imbalance and cell death. Erastin's unique ability to selectively target this axis makes it essential for exploring ferroptosis mechanisms and potential therapeutic interventions in oncology. This article extends the mechanistic context provided in Erastin and the Translational Leap: Harnessing Ferroptosis by focusing on quantitative experimental parameters and molecular selectivity.

Mechanism of Action of Erastin

Erastin acts by two primary molecular mechanisms:

• Inhibition of the cystine/glutamate antiporter (system Xc⁻): Erastin binds to and inhibits SLC7A11, the light chain subunit of system Xc⁻, reducing cystine uptake and lowering intracellular glutathione (GSH) (Zhang et al., 2023).
• Modulation of voltage-dependent anion channel (VDAC): Erastin alters VDAC permeability, impacting mitochondrial function and promoting ROS generation (B-RAF, 2023).

The combined effect is an accumulation of ROS, especially lipid hydroperoxides, ultimately causing ferroptotic cell death. Unlike apoptosis, this pathway is caspase-independent and is not rescued by classical apoptosis inhibitors. Recent studies also highlight the role of lipid metabolism enzymes, such as ACSL1 and FSP1, in modulating ferroptosis sensitivity (Zhang et al., 2023).

Evidence & Benchmarks

• Erastin induces ferroptosis in RAS/BRAF-mutant tumor cells via system Xc⁻ inhibition and VDAC modulation (DOI:10.1038/s41420-023-01385-2).
• Erastin treatment (10 μM, 24 h, HT-1080 cells) results in increased lipid peroxidation and reduced cell viability, confirming ferroptosis (APExBIO Product Data).
• Ferroptosis induced by Erastin is not inhibited by caspase blockers, distinguishing it from apoptotic cell death (Mutant IDH1-IN-1, 2023).
• Cells with elevated ACSL1 or FSP1 expression exhibit resistance to Erastin-induced ferroptosis, suggesting key modulators in the pathway (DOI:10.1038/s41420-023-01385-2).
• Erastin is highly soluble in DMSO (≥10.92 mg/mL at 25°C with warming), but insoluble in water and ethanol (APExBIO Product Page).

For a more in-depth comparison of Erastin's mechanistic profile versus similar compounds, see Erastin: A Precision Ferroptosis Inducer for Cancer Biology, which this article extends by providing updated solubility and workflow data.

Applications, Limits & Misconceptions

Primary Applications:

• Dissecting ferroptosis mechanisms in RAS/BRAF-mutant tumor models
• Evaluating redox homeostasis and oxidative stress response in cancer biology
• Testing new cancer therapies targeting ferroptosis pathways
• Screening for ferroptosis resistance factors (e.g., ACSL1, FSP1)

Erastin is less effective in non-tumorigenic or ferroptosis-resistant cell lines, especially those with high FSP1 or ACSL1 expression levels. Its action is independent of caspase activation and is not suitable for studies restricted to classical apoptosis. This article updates and clarifies the workflow and resistance context compared to Erastin and the Next Frontier in Ferroptosis Research, particularly regarding limits in non-malignant settings.

Common Pitfalls or Misconceptions

• Erastin does not induce apoptosis: Its effects are caspase-independent and cannot be blocked by pan-caspase inhibitors (Zhang et al., 2023).
• Resistance in high-FSP1/ACSL1 cells: Cells overexpressing these proteins are less sensitive to Erastin-induced ferroptosis.
• Solubility constraints: Erastin must be dissolved in DMSO; aqueous or ethanol-based solvents are ineffective (APExBIO).
• Instability in solution: Fresh solutions are required; Erastin degrades over time in DMSO at room temperature.
• Not suitable for in vivo systemic studies: Lack of validated pharmacokinetics limits use to in vitro/ex vivo systems.

Workflow Integration & Parameters

For optimal results, Erastin (APExBIO, B1524) should be stored at -20°C as a solid. Prepare solutions freshly in DMSO at ≥10.92 mg/mL with gentle warming. Typical experimental conditions involve treating engineered human cancer cell lines or HT-1080 fibrosarcoma cells at 10 μM for 24 hours. Erastin is compatible with a range of oxidative stress assays, including C11-BODIPY lipid peroxidation and GSH quantification. Controls should include ferroptosis inhibitors (e.g., Ferrostatin-1) to confirm pathway specificity. For workflow reproducibility, avoid prolonged storage of Erastin solutions; always use freshly prepared aliquots. This extends prior workflow guidance from Erastin: A Ferroptosis Inducer Transforming Cancer Research by specifying temperature, solvent, and timing requirements.

Conclusion & Outlook

Erastin, as provided by APExBIO, remains the gold-standard reagent for inducing and dissecting ferroptosis in RAS/BRAF-mutant tumor models. Its well-characterized mechanism, validated benchmarks, and robust workflow recommendations enable high-fidelity research in cancer biology and redox signaling. With expanding interest in ferroptosis as a therapeutic target, Erastin will continue to inform both foundational discovery and translational oncology research. For product specifications and ordering, visit the APExBIO Erastin product page.